Clearmind Medicine announces international patent application for Ibogaine combo

Clearmind Medicine (CMND) announced the publication of an international patent application under the Patent Cooperation Treaty for its combination therapy of Ibogaine and N-Acylethanolamines. Ibogaine, a key compound derived from the root of Tabernanthe iboga, a shrub native to West and Central Africa, has shown promise in human clinical trials for treating opioid use disorder, cocaine use disorder, and other substance use disorders. As a result, Ibogaine is considered a potentially effective anti-addiction agent. The patent application follows developments from Clearmind’s collaboration with SciSparc (SPRC), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide.